# Danaher Corporation (DHR) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $207.66, market value $146.0 billion.

## Valuation
- **P/E (trailing): 37.0×** (5-yr avg 36.2×, 3-yr avg 41.3×). Danaher Corporation trades at 37.0× trailing earnings, close to its own five-year average of 36.2×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 22.3×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 5.8×**. Each dollar of revenue is priced at 5.8×.
- **Price / book: 2.8×**. The shares trade at 2.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 3.7%** (5-yr avg 3.5%). Free cash flow equals 3.7% of the market value, in line with its five-year average of 3.5%.
- **Earnings yield: 2.7%**. The inverse of the P/E: 2.7% of the price is earned each year.

## Profitability
- **Gross margin: 58.5%**. Danaher Corporation keeps 58.5% of revenue after the direct cost of what it sells.
- **Operating margin: 20.4%**. 20.4% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 14.7%**. 14.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 6.9%**. 6.9% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 5.7%**. Return on all capital, debt included, is 5.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 4.8%**. Each dollar of assets produces 4.8% of profit.

## Growth
- **Revenue growth (1 yr): 2.9%** (3-yr -2.7%/yr, 5-yr 2.0%/yr). Revenue grew 2.9% over the last year, against 2.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -4.5%** (3-yr -19.4%/yr, 5-yr 0.6%/yr). Earnings per share fell 4.5%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -10.8%/yr**. Free cash flow has compounded at -10.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.35**. Debt is 0.35 times equity: a conservative balance sheet.
- **Current ratio: 1.87** (quick 1.87). Current assets cover the next year's liabilities 1.87 times.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.77%** ($1.44 per share, trailing). Danaher Corporation yields 0.77%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 24%** (18% of free cash flow). 24% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 8**. 8 straight years of increases.
- **Dividend growth (5 yr): 14.9%/yr** (1-yr 18.5%). The dividend has compounded at 14.9% a year over five years, doubling roughly every 5 years at that pace.

## Analyst view
- **Analyst consensus: strong_buy** (23 analysts). 23 analysts cover Danaher Corporation; the consensus is strong_buy, with an average price target of $227.96 (+10% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 5.1%** (YTD -8.9%, 3-mo 12.9%). The shares are up 5.1% over twelve months including dividends.
- **From 52-week high: -14.5%** (29.0% above the low). Trading 14% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 0.47** (volatility 31%). Beta of 0.47 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DHR · Page: https://foliofundamentals.com/stocks/dhr

Not investment advice.